Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non-Current Assets for 10 consecutive years, with $671000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 45.24% to $671000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $671000.0, a 45.24% increase, with the full-year FY2024 number at $464000.0, up 41.46% from a year prior.
  • Other Non-Current Assets was $671000.0 for Q3 2025 at Rhythm Pharmaceuticals, up from $527000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $671000.0 in Q3 2025 to a low of $328000.0 in Q1 2021.
  • A 5-year average of $391789.5 and a median of $328000.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: fell 18.61% in 2021, then surged 45.24% in 2025.
  • Rhythm Pharmaceuticals' Other Non-Current Assets stood at $328000.0 in 2021, then changed by 0.0% to $328000.0 in 2022, then changed by 0.0% to $328000.0 in 2023, then soared by 41.46% to $464000.0 in 2024, then skyrocketed by 44.61% to $671000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Other Non-Current Assets are $671000.0 (Q3 2025), $527000.0 (Q2 2025), and $464000.0 (Q1 2025).